Thank you for donating!

You can donate using the following services.


  1. 27.04.21

    Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

    Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on and is preparing to commence its pivotal Phase 3 study evaluating Trappsol® Cyclo™...

    Read more
  2. 15.04.21

    Tony Jellings: Former NPUK Trustee & Fundraising Coordinator

    As we celebrate our milestone 30th year as a small charity, we are pleased to be joined by another instrumental former member of the Niemann-Pick UK Board of Trustees, Tony Jellings. Tony has kindly provided us with the following article which provides more detail surrounding his family's connection with Niemann-Pick disease, and his fantastic support throughout the years that followed...

    Read more
  3. 14.04.21

    Cyclo Therapeutics Inc: Update (13/4/21)

    Read more
  4. 25.03.21

    Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

    Read more
  5. 16.03.21

    University College London begins preclinical studies to develop a treatment for Niemann Pick C disease with support from the Columbus Foundation

    Read more